SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has won six 2019 Life Science Leader CMO Leadership Awards. The company won in every category: Quality, Capabilities, Compatibility, Expertise, Reliability, and Service across all three groups of respondents (Big Pharma, Small Pharma and Overall (combined Big and Small Pharma).
This is the fifth time in the CMO Leadership Awards program's eighth year that SEQENS has been awarded multiple awards, including across all six major categories. The company has now won 30 CMO Leadership Awards since 2014. The awards will be presented at The CMO Leadership Awards Reception at Convene, at 237 Park Avenue on March 20, 2019 in NYC.
For the 2019 CMO Leadership Awards, Life Science Leader magazine teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 120 contract manufactures were assessed by 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey. Survey participants were recruited from Pharma and Biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with contract manufacturers and clear experiential data.
"Each year, the value that CMOs bring to individual biotech and pharma companies increases, as does the overall importance of the service sector to our entire and global drug development and manufacturing industry," said Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
"Amid growing industry competition, the fact that SEQENS North America continues to win CMO Leadership Awards, especially across all categories, is a testament to our people, training and equipment as well as to our results-driven culture ? particularly since winners are based on input from people who work with us," said Ed Price, president and CEO of SEQENS North America. "While we're now known as SEQENS North America, part of a global CDMO that can offer more resources and even deeper expertise, our commitment to being responsive to our sponsors remains a core value."
SEQENS North America, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, has a portfolio of commercially approved products that now includes nine commercial products that either have or are imminently receiving FDA approval for sale in the U.S. The division has more than 17 API and other advanced materials products in its pipeline.
About SEQENS North America
SEQENS North America (formerly PCI Synthesis) is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass., a division of SEQENS, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia.
SEQENS North America is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, SEQENS North America provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about SEQENS North America, its proprietary NCE development activities and process R&D capabilities please visit www.seqens.com.
These press releases may also interest you